Clinical Trial Update: Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of an HLA-A*2402 restricted peptide vaccine for advanced esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• HLA-A*2402 Restricted Peptide Vaccine Therapy

Snippet

Sponsor: Kinki University | Conditions: Esophageal Cancer | Phase 1 | Status: COMPLETED